FDA reform health claims provision would "tie FDA's hands," CSPI's Silverglade says.
This article was originally published in The Tan Sheet
Executive Summary
FDA REFORM HEALTH CLAIMS PROVISION WOULD "TIE FDA's HANDS," CSPI Director of Legal Affairs Bruce Silverglade asserted at a July 7 Washington, D.C. press briefing on the Senate FDA reform bill (S 830) sponsored by Public Citizen, the Consumer Federation of America and the Patients' Coalition. Speaking for the Center for Science in the Public Interest, Silverglade maintained that, if passed as currently constructed, the FDA Modernization and Accountability Act would "tie FDA's hands and make it impossible for the agency to promptly prohibit misleading health claims on food labels."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning